{
  "id": 18796700,
  "title": "Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials",
  "url": "https://urgent.news/2026/11/07/forget-lilly-and-novo-pfizer-is-planning-a-wave-of-phase-3-obesity",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-07T21:15:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/07/forget-lilly-and-novo-pfizer-is-planning-a-wave-of/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Pfizer, once an underdog in the pharmaceutical world, is poised to disrupt the obesity drug market with a series of Phase 3 trials. Despite initially withdrawing from GLP-1 drug development, Pfizer has since acquired a promising candidate and is now racing to bring a monthly injection option to market. This convenience factor could give Pfizer's product an edge over the once-weekly or daily injections offered by competitors Novo Nordisk and Eli Lilly. With a robust pipeline of 10 late-stage trials, Pfizer is well-positioned to capture a significant share of the growing GLP-1 market. Investors may have underestimated Pfizer's potential, as evidenced by the company's 5.5% dividend yield, which outpaces its peers. As a long-term dividend investor, now may be an opportune moment to consider adding Pfizer to your portfolio, particularly as the company edges closer to an approved GLP-1 product.",
  "summary": "Everyone is talking about the GLP-1 battle between Eli Lilly and Novo Nordisk, but Pfizer wants in on the fight, too.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials",
        "url": "https://urgent.news/2026/11/07/forget-lilly-and-novo-pfizer-is-planning-a-wave-of-phase-3-obesity-18797888",
        "published": "2026-11-07T21:35:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}